A recent survey by Norton Rose Fulbright found that increasing cybersecurity and data privacy concerns have had an impact on recent litigation.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
